AUTHOR INFORMATION

Section 1 of 12

Authored by Daniel Noltkamper, MD, FACEP, Medical Director, Department of Emergency Medicine, Naval Hospital of Camp Lejeune

Coauthored by Stephen W Burgher, MD, FACEP, Assistant Medical Director, Department of Emergency Medicine, Baylor University Medical Center

Daniel Noltkamper, MD, FACEP, is a member of the following medical societies: American College of Emergency Physicians

Edited by Miguel C Fernandez, MD, FACEP, FAAEM, FACMT, Associate Clinical Professor; Medical and Managing Director, South Texas Poison Center, Department of Surgery/Emergency Medicine and Toxicology, University of Texas Health Science Center at San Antonio; John T VanDeVoort, PharmD, Clinical Assistant Professor, College of Pharmacy, University of Minnesota; Fred Harchelroad, MD, FACMT, Chair, Department of Emergency Medicine, Director of Medical Toxicology, Associate Professor, Department of Emergency Medicine, Allegheny General Hospital; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; and Asim Tarabar, MD, Assistant Clinical Professor of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Author's Email:	Daniel Noltkamper, MD, FACEP
Editor's Email:	Miguel C Fernandez, MD, FACEP, FAAEM, FACMT

eMedicine Journal, January 11 2007, VOLUME 8, Number 1

INTRODUCTION

Section 2 of 12

Background: Phosgene (COCl₂) is a highly toxic gas or liquid that is classified as a pulmonary irritant. Synonyms for phosgene include carbonic dichloride, carbon oxychloride, carbonyl dichloride, chloroformyl chloride, d-stoff, and green cross. The military symbol for phosgene is CG, and its United Nations/Department of Transportation number is UN#1076. The American Chemical Society's Chemical Abstracts Service (CAS) registry number for phosgene is #75-44-5.

Sir Humphrey Davy first synthesized phosgene in 1812 by passing carbon monoxide and chloride through charcoal. During World War I, it was used in combination with chlorine gas for combat purposes by the German army. This combination allowed phosgene emission to be hastened in cold weather. The German army switched to mustard gas in 1917 because of the development of effective gas masks. More effective agents and improved personal protective equipment make phosgene an unlikely agent to be used in future battles.

Present day exposure occurs during the manufacture of aniline dyes, polycarbonate resins, coal tar, pesticides, isocyanates, polyurethane, and pharmaceuticals. Phosgene exposure also occurs in the uranium enrichment process and during the bleaching of sand for glass production. Exposures related to the heating or combustion of chlorinated organic compounds, such as carbon tetrachloride, chloroform, and methylene chloride, also occur. These products are found in common household solvents, paint removers, and dry cleaning fluids. Occupational exposure can occur when welders heat metals treated with these chemicals and in organic chemistry laboratories that use chloroform. Similarly, vehicle crashes involving trains or trucks transporting phosgene (or chlorinated hydrocarbons, such as methylene chloride, that could combust to form phosgene) could expose numerous individuals to this toxin.

Pathophysiology: Phosgene is a colorless gas with the odor of newly mown hay or green corn. Olfactory fatigue may occur with a large exposure. Exposure to concentrations of 3 ppm may not cause noticeable symptoms for 12-24 hours. Exposures to 50 ppm may be rapidly fatal. While an odor threshold of 1.5 ppm has been reported in some humans, this does not protect against toxic inhalation effects.

Phosgene is considered to have poor warning properties and, hence, may reach the lower airways before it is noticed. It is 4 times heavier than air and is a gas above 47°F (8°C). Because of hydrolysis from atmospheric water, it appears as a white cloud in an outside environment.

There are 2 mechanisms of injury, hydrolysis and acylation. In hydrolysis, damage caused by phosgene is due to the presence of a highly reactive carbonyl group attached to 2 chloride atoms. The gas dissolves slowly in water, but when this occurs, it hydrolyses to form carbon dioxide and hydrochloric acid. This slow dissolution allows phosgene to enter the pulmonary system without significant damage to the upper airways. However, in the lower airways and alveoli, the tissue undergoes necrosis and inflammation. After the first few hours of exposure, the carbonyl group attacks the surface of the alveolar capillaries, causing leakage of serum into the alveolar septa. The tissue fills with fluid, causing hypoxia and apnea. Massive amounts of fluid (up to 1 L/h) leak out of the circulation, leading to a noncardiogenic pulmonary edema, with associated hypoxemia and volume depletion.

Acylation involves the reaction of phosgene with nucleophilic moieties causing denaturation of proteins, changes in cell membranes, and disruption of enzymes. The permeability of the blood-air barrier is altered, leading to interstitial edema, and the inflammatory cascade is activated. This primarily occurs in the bronchioli and alveoli since they are not protected by a mucous layer.

Researchers in the past decade have discovered 2 important facts that may lead to improved therapy. First, phosgene stimulates the synthesis of lipoxygenase-derived leukotrienes. Second, phosgene combines with glutathione to form diglutathionyl dithiocarbonate. When the glutathione stores become depleted, phosgene binds to the cellular macromolecules, causing cell necrosis in the renal and hepatic tissues.

Frequency:

• In the US: Clinically significant phosgene exposure occurs infrequently. Sporadic exposures in recent years are related to industrial accidents or isolated.

• Internationally: In view of currently available war gases, which are much more lethal than phosgene, and improved respiratory protection, phosgene is no longer considered a significant threat.

Mortality/Morbidity: The Occupational Safety and Health Administration permissible exposure limit (OSHA PEL) for the workplace is 0.1 ppm (0.4 mg/m) as an 8-hour time weighted average. The level immediately dangerous to life or health (IDLH) is 2 ppm. Even a short exposure to 50 ppm may result in rapid fatality.

Another means to assess exposure and potential complications is using the inhaled dose instead of concentration alone. An inhaled dose of greater than 25 ppm-min leads to subclinical biochemical lung alterations, greater than 150 ppm-min causes overt alveolar edema, greater than 300 ppm-min is possibly lethal, and the level with 50% mortality is about 500 ppm-min.

• During World War I, from December 1915 to August 1916, casualties from phosgene exposure occurred in 4.1% of gas-exposed troops. Fatality from phosgene exposure occurred in 0.7% of gas-exposed troops. Total casualties from chemical gas exposure occurred in 1.2 million troops and caused 100,000 deaths. Phosgene accounted for an estimated 80% of these cases.

• According to OSHA, millions of kilograms of phosgene are produced annually, with 10,000 workers at risk of exposure. This does not include the large number of people that may have mild-to-moderate exposures in their homes from using solvents (eg, methylene chloride) with heat guns to remove paint.

• Morbidity and mortality are related to the degree of pulmonary insult and subsequent hypoxemia. Delayed diagnosis may result from delayed signs and symptoms. Underlying medical conditions contribute to the patient's ability to withstand the hypoxic insult.

Race: No evidence has demonstrated that outcome of phosgene toxicity is dependent on race.

Sex: No sex predilection exists. Historically, most exposures have occurred in men because of their military roles. Women were exposed during World War I from developing and testing gas masks at the home front.

CLINICAL

Section 3 of 12

History: Diagnosis of phosgene toxicity depends largely on history of exposure. Consider phosgene toxicity in patients involved in the manufacture of dyes, resins, coal tar, and pesticides. Query patients regarding occupation and any exposure to chemicals, especially around sources of heat. In the work setting and at home, phosgene can be produced by the combustion of methylene chloride (paint remover) or trichloroethylene (a degreasing solvent). Patients typically have an asymptomatic period of 30 minutes to 72 hours, but most significant exposures have a latent period less than 24 hours. The duration and concentration of exposure determine the time to symptom onset.

• Pulmonary

• Cough (initially nonproductive, later frothy white-to-yellow sputum) or hemoptysis

• Dyspnea (exertional early on, subsequently becomes resting dyspnea)

• Chest tightness or discomfort (may be pleuritic but frequently is described as retrosternal burning)

• Head, ears, eyes, nose, and throat

• Mucosal irritation - More common with intense exposure

• Eye irritation and tearing

• Nasal irritation (irritation and burning of the nasal passages) - Occurs with phosgene concentrations higher than 3 ppm, but, with lower respiratory tract disease, may occur at even lower concentrations

• Throat irritation extending to the retrosternal area - Common with exposures more than 5 ppm and may be described as a burning sensation

• Sudden death secondary to laryngospasm with large exposures

• Cardiovascular (caused by volume depletion or hypoxemia)

• Lightheadedness, palpitations

• Angina

• Headache (thought to be secondary to the hypoxemia and the inflammatory response initiated in the pulmonary parenchyma)

• Anorexia, nausea, and vomiting

• Flat metallic taste when smoking cigarettes or overall altered taste sensation

• Weakness

• Anxiety and sense of impending doom (likely from the hypoxemia and tachycardia)

• Skin burning if the patient has been sweating or if clothing is wet (caused by the breakdown to hydrochloric acid)

Physical: Physical examination is useful with patients with active symptoms. Patients who relate a recent exposure may be in the latent phase and have no specific findings related to the exposure.

• Pulmonary

• Tachypnea and bronchorrhea

• Wheezes, crackles, or rales on auscultation

• Cyanosis

• Apnea (late finding)

• Head, ears, eyes, nose, and throat (Upper airway findings are not good prognostic indicators because significant injury may occur to the lower airways without upper airway involvement.)

• Conjunctival injection and lacrimation

• Oropharyngeal hyperemia and salivation

• Nasal mucosa hyperemia associated with rhinorrhea

• Cardiovascular

• Tachycardia

• Hypotension

• Skin

• Cyanosis from pulmonary injury and resultant hypoxemia

• Chemical burns from liquefied phosgene (Although it also is considered a frostbite hazard in the compressed liquid form)

Causes: The major risks are occupational exposure and close proximity to an industrial incident.

• Present day exposures described in literature are caused by the combustion products from chlorinated chemicals (eg, methylene chloride, trichloroethylene).

• Welding metals recently treated with degreasers, such as trichloroethylene, may produce phosgene. Solvents used for degreasing purposes should be stored more than 200 feet from a welding arc, as the exposure to UV light can create phosgene by photodegradation.

• Use of methylene chloride, a commonly used chemical paint remover, near a heat source allows the release of phosgene.

• Carbon monoxide is released in vivo as a metabolic product of methylene chloride.

• Phosgene is a breakdown product of chloroform that is stored for more than 6 months, even if the chloroform is stabilized with amylene.

DIFFERENTIALS

Section 4 of 12

Acute Coronary Syndrome
Acute Respiratory Distress Syndrome
Altitude Illness - Pulmonary Syndromes
Bronchitis
CBRNE - Chemical Warfare Agents
Congestive Heart Failure and Pulmonary Edema
EMS and Terrorism
Hantavirus Cardiopulmonary Syndrome
Hazmat
Pneumonia, Bacterial
Pneumonia, Mycoplasma
Pneumonia, Viral
Pulmonary Embolism
Respiratory Distress Syndrome, Adult
Smoke Inhalation
Toxicity, Ammonia
Toxicity, Carbon Monoxide
Toxicity, Chlorine Gas
Toxicity, Cyanide
Toxicity, Hydrocarbon Insecticides
Toxicity, Hydrogen Sulfide
Toxicity, Organophosphate and Carbamate
Toxicity, Phosgene

Other Problems to be Considered:

Phosphorus pentoxide exposure (white phosphorus weaponry)
Sulfur dioxide exposure

WORKUP

Section 5 of 12

Lab Studies:

• ABG with carboxyhemoglobin and methemoglobin levels

• ABG demonstrates the degree of hypoxemia. A partial pressure of oxygen (pO₂) as low as 23 mm Hg on 8 L/min of oxygen by face mask has been reported.

• Typical presenting pO₂ levels are 50-60 mm Hg while breathing room air.

• The carboxyhemoglobin level is important for cases involving exposure to methylene chloride or when carbon monoxide exposure is suspected. Methemoglobinemia may suggest other causes.

• CBC

• CBC may be obtained as a baseline level or if pneumonia is high on the differential diagnosis list. An elevated WBC count is not specific because it may result from hypoxemic stress or an infectious process.

• CBC may reveal hemoconcentration late in the disease process.

• Electrolytes may be obtained as baseline studies because of the anticipated large fluid shifts that occur.

• Cardiac enzymes (eg, creatine kinase-MB [CK-MB], troponin T, troponin I) may be obtained if cardiogenic pulmonary edema is high on the differential.

• Continue pulse oximetry and cardiac monitoring in patients suspected of phosgene toxicity.

• Investigation on a blood test that measures exposure to phosgene is being pursued. Most likely, this test will be used in laboratory settings.

Imaging Studies:

• Chest x-ray

• Initial findings may be normal; however, as the disease progresses, the chest x-ray (CXR) may demonstrate bilateral, diffuse interstitial infiltrates.

• Heart and pulmonary vessel sizes are usually normal unless the patient has baseline cardiomegaly.

• CXR findings may precede the clinical presentation.

Procedures:

• Perform endotracheal (ET) intubation and mechanical ventilation based on the degree of respiratory failure and overall clinical picture.

TREATMENT

Section 6 of 12

Prehospital Care:

• To avoid further exposures, hazardous materials (Hazmat) prehospital providers should always ensure that the environment is safe.

• A self-contained breathing apparatus (SCBA) should be worn at the exposure site. Remove the patient's clothes to prevent further contamination.

• If the eyes and skin are exposed, begin irrigation onsite.

• In the field, standard management of ABCs usually is sufficient. Severe exposures may require ET intubation and suctioning. If a significant bronchospastic component is present, bronchodilators may be used with caution.

• Past wartime experience has demonstrated that, in a mass casualty situation, phosgene exposures should be classified as immediate because of the impending need for intubation and positive end-expiratory pressure (PEEP) to maintain distal airway opening.

Emergency Department Care: Always consider the need for decontamination in any toxic exposure to minimize the risk of poisoning hospital personnel. Inhalational exposure of phosgene should not occur unless in the proximity of the gas. If external decontamination has not been performed in the field, use personal protective equipment, as necessary, including dermal, eye, and facial protection. A decontamination shower unit may be used.

• Initiate humidified oxygen supplementation. Intubation with continuous positive airway pressure (CPAP) ventilation and pressure support is usually required to improve oxygenation. Frequent suctioning may improve conditions.

• Bronchodilators may improve existing bronchospasm. In animal studies, beneficial effect has been shown with the administration of numerous drugs, including leukotriene antagonists, ibuprofen, colchicine, cyclophosphamide, terbutaline, aminophylline, and N-acetylcysteine. Nebulized sodium bicarbonate treatment theoretically may be beneficial; however, consider it as second line after the drugs noted above.

• Avoid excessive fluid administration. Pulmonary artery catheter monitoring may be required to maintain appropriate fluid balance while treating hypotension caused by fluid shifts.

• In severe cases, extracorporeal membrane oxygenation (ECMO) may be considered refractory to supportive care.

• Minimize fluid administration except when it is needed to correct hypotension. Avoid diuretics because the patient typically is volume-depleted from fluid shifts.

• Avoid exertion during treatment and for several weeks after recovery.

• Prophylactic antibiotics have been recommended by some authors based on the findings of pneumonia and bronchitis in virtually all autopsy specimens.

• Corticosteroid administration postexposure has been recommended to reduce the degree of pulmonary edema by reducing the inflammatory response. Some sources recommend administration begin within 15 minutes or as soon as possible after exposure.

• No specific antidote or effective elimination process exists. During both world wars, the Germans and Russians believed that hexamethylene tetramine was the antidote. Subsequent studies have shown some preexposure benefit but no definite postexposure benefit.

• Tomelukast, a leukotriene receptor antagonist, prevents pulmonary edema in phosgene-exposed rabbits. Experimentally, ibuprofen has been shown to reduce phosgene-induced pulmonary edema. Colchicine and cyclophosphamide reduce neutrophil influx when administered to mice 30 minutes following phosgene exposure. These drugs reduce lung injury and mortality in mice.

• Intratracheal dibutyryl cyclic adenosine monophosphate (DBcAMP), a cyclic adenosine monophosphate (cAMP) analogue, inhibits the release of leukotrienes that contribute to the disease process. In phosgene-exposed rabbits, terbutaline and aminophylline (cAMP enhancers) limit the pulmonary capillary leakage. Also, intratracheal N-acetylcysteine (NAC), administered to rabbits 45 minutes postexposure, reduces leukotriene formation and pulmonary edema. Theoretically, nebulized NAC also should be effective.

Consultations:

• Consult the regional poison control center and a medical toxicologist for additional useful information and patient care recommendations.

• Prolonged critical care management often is required for the pulmonary complications of phosgene exposure.

MEDICATION

Section 7 of 12

Management of phosgene toxicity is supportive. Oxygen, corticosteroids (inhaled, systemic), leukotriene inhibitors, IV fluids, and prophylactic antibiotics are recommended. The recommended steroid dose is much higher than the dose conventionally used in asthma. Prophylactic antibiotics and antifungals may be required because of the risk of superinfection. Pressor agents may be required to treat hypotension, bradycardia, and renal failure.

Drug Category: Corticosteroids -- Reduce inflammatory response. Whether early administration of corticosteroids can prevent development of noncardiogenic pulmonary edema is unknown. The decision to administer corticosteroids must be made on clinical grounds.

Treatments lasting more than 1 week may require a taper to prevent abrupt steroid withdrawal.

Drug Name	Dexamethasone (Decadron) -- Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reducing capillary permeability.
Adult Dose	4 puffs immediately followed by 1 puff q3min until any sense of irritation is gone; then 5 puffs q15min until 1 inhaler is exhausted; followed by a daily regimen of 1 puff qh during the day and 5 puffs q15min for 90 min before sleep; repeat for at least 5 d
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity
Interactions	Effects decrease with coadministration of barbiturates, phenytoin, and rifampin; decreases effect of salicylates and vaccines used for immunization
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Increases risk of multiple complications, including severe infections; monitor adrenal insufficiency when tapering drug; abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections are possible complications of glucocorticoid use

Drug Name	Beclomethasone (Beclovent, Vanceril) -- Inhibits bronchoconstriction mechanisms, producing direct smooth muscle relaxation; may decrease number and activity of inflammatory cells, in turn decreasing airway hyperresponsiveness.
Adult Dose	10 puffs immediately followed by 5 puffs qh for 10 h; then 1 puff qh for at least 5 d
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity; bronchospasm, status asthmaticus, and other types of acute episodes of asthma
Interactions	Coadministration with ketoconazole may increase plasma levels but does not appear to be clinically significant
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Weight gain, increased bruising, cushingoid features, acneiform lesions, mental disturbances, and cataracts may occur (taper medication slowly if these changes occur)

Drug Name	Methylprednisolone (Solu-Medrol) -- Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
Adult Dose	Day 1: 1000 mg IV Days 2-3: 800 mg IV Days 4-5: 700 mg IV Day 6: Reduce dose quickly if chest x-ray remains clear
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity
Interactions	Coadministration with digoxin may increase digitalis toxicity secondary to hypokalemia; estrogens may increase levels; phenobarbital, phenytoin and rifampin may decrease levels (adjust dose); monitor patients for hypokalemia when taking medication concurrently with diuretics
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Hyperglycemia, edema, osteonecrosis, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, growth suppression, myopathy, and infections are possible complications; caution in viral, fungal, or tubercular skin infections

Drug Name	Betamethasone (Celestone, Soluspan) -- Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
Adult Dose	Begin with 20 mg IV; repeat q6h IV/IM for 24 h; reduce dose over next 5 d
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity
Interactions	Effects decrease with coadministration of barbiturates, phenytoin, and rifampin; dexamethasone decreases effect of salicylates and vaccines used for immunization
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Increases risk of multiple complications, including severe infections (caution in tubercular or systemic fungal infections); monitor adrenal insufficiency when tapering drug; abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections are possible complications

Drug Category: Vasopressors -- Used to treat hypotension, bradycardia, or renal failure.

Drug Name	Dopamine (Intropin) -- Stimulates adrenergic and dopaminergic receptors. Hemodynamic effect is dependent on the dose. Lower doses predominantly stimulate dopaminergic receptors that, in turn, produce renal and mesenteric vasodilation. Use low dose to protect renal function; use high dose to combat severe hypotension unresponsive to fluid administration.
Adult Dose	2-20 mcg/kg/min IV; titrate to effect
Pediatric Dose	Administer as in adults
Contraindications	Documented hypersensitivity; pheochromocytoma or ventricular fibrillation
Interactions	Phenytoin, alpha- and beta-adrenergic blockers, general anesthesia, and MAOIs increase and prolong effects
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Closely monitor urine flow, cardiac output, pulmonary wedge pressure, and blood pressure during the infusion; before infusion, correct hypovolemia with whole blood or plasma prn; monitoring central venous pressure or left ventricular filling pressure may be helpful in detecting and treating hypovolemia

Drug Category: Leukotriene antagonists -- Reduce the inflammatory response elicited by the leukotriene cascade. Leukotriene antagonists are approved by the Food and Drug Administration (FDA) only for chronic asthma management.

Drug Name	Zafirlukast (Accolate) -- No human studies have evaluated the efficacy and safety of zafirlukast in patients exposed to phosgene. Nevertheless, given the known effects of leukotriene stimulation by phosgene, the results from animal studies, and the drug’s safety profile, should be considered first line. In the presence of food, bioavailability of oral zafirlukast is decreased by 40%. Administer on an empty stomach.
Adult Dose	20 mg q12h PO asthma; however, given the pharmacokinetic profile and the exaggerated response caused by phosgene, an increased dosage can be assumed (consider 40-80 mg PO q12h for the initial 48 h)
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity
Interactions	Aspirin increases plasma levels; erythromycin decreases plasma levels; theophylline may decrease levels and may increase plasma theophylline levels; warfarin may result in clinically significant increases in half-life of warfarin
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Severe liver disease; concomitant warfarin therapy; systemic eosinophilia, and symptoms consistent with Churg-Strauss syndrome have been reported during reduction in oral steroid therapy; efficacy and safety in humans exposed to phosgene have not been validated in clinical trials

FOLLOW-UP

Section 8 of 12

Further Inpatient Care:

• Admit patient to an intensive care setting for continued monitoring and supportive care. Improvement typically occurs within 48-72 hours.

Further Outpatient Care:

• In a case of suspected exposure to phosgene, monitor the patient for a minimum of 12-24 hours because of the potential for delayed-onset pulmonary edema. (The patient must remain asymptomatic and have no chest x-ray changes or hypoxemia after observation to be released from the ED or inpatient ward.)

• Instruct patients discharged from the hospital after recovery from pulmonary edema to avoid exertion and any pulmonary toxins that may precipitate a recurrence. Also, instruct patients to avoid circumstances similar to their exposure and to warn others of the same dangers.

Transfer:

• Provide supplemental oxygen and/or bilevel positive airway pressure (BiPAP) and immediately transfer patients to an appropriate facility if they present to clinics or hospitals without endotracheal intubation capability, ventilator capability, or ICU monitoring.

Deterrence/Prevention:

• A standard field protective mask or gas particulate filter provides adequate protection.

• Personnel working with chlorinated hydrocarbon compounds should ensure adequate ventilation and avoid exposing the compounds and the vapors to heat or UV sources.

Complications:

• Recurrence of pulmonary edema because of exertion, re-exposure, or exposure to other pulmonary toxins

• Pneumonia

• Development of reactive airway dysfunction syndrome with bronchospasm and chronic airway inflammation

Prognosis:

• The prognosis of acute phosgene exposure is good with early intervention. Few significant long-term sequelae occur after recovery.

• Studies involving combat personnel and workers involved in the uranium enrichment process have shown increased morbidity and mortality with high level exposure because of the development of pneumonitis, chronic bronchitis, emphysema, and impaired pulmonary function.

• The degree of the patient’s cyanosis provides a rough estimate of survivability. Historically, patients with a mouse grey cyanosis have a worse prognosis than those with a plum blue cyanosis (quantitative assessment of hypoxemia was not routinely available at the time of these historical observations). To estimate the time until respiratory failure, double the length of time from exposure to the development of crackles.

Patient Education:

• Instruct patients to avoid future exposures and to educate others involved in similar practices. Patients should minimize exertion for several weeks. Determining factors for return to the ED should include the symptoms of cough recurrence, dyspnea (especially resting dyspnea), and chest discomfort.

• For excellent patient education resources, visit eMedicine's Bioterrorism and Warfare Center and Poisoning Center . Also, see eMedicine's patient education articles Chemical Warfare, Personal Protective Equipment, and Carbon Monoxide Poisoning.

MISCELLANEOUS

Section 9 of 12

Medical/Legal Pitfalls:

• Failure to consider the asymptomatic period and delayed onset of symptoms associated with phosgene toxicity and discharging the patient from the ED without an adequate period of observation

• Failure to ascertain a history consistent with phosgene exposure

• Failure to recognize phosgene as a combustion product of certain chemicals, especially chlorinated compounds (eg, methylene chloride, trichloroethylene)

• Failure to associate phosgene with the manufacturing process of common chemicals (eg, methyl isocyanate)

• Failure to consider phosgene toxicity in patients who present dyspnea or chest discomfort and who have occupations (eg, welding, refinishing) with increased risk of exposure

• Administering diuretics to a volume-depleted patient, causing further circulatory collapse

• Failure to consider secondary pneumonia in patients not responding after 2-3 days of aggressive therapy

• Failure to recognize early signs of significant respiratory distress and document either a pO₂ or oxygen saturation via pulse oximetry

• Failure to monitor the patient in a setting where respiratory support is immediately available or failure to transfer the patient to a facility with appropriate respiratory support capability

• Failure to consider carbon monoxide poisoning from exposure to methylene chloride

• Failure to evaluate and treat possible angina or myocardial infarction

Special Concerns:

• The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the US government.

TEST QUESTIONS

Section 10 of 12

CME Question 1: A 24-year-old welder presents with 2 hours of exertional dyspnea and a painful dry cough 20 hours after welding an object previously treated with a degreasing compound. His vital signs reveal tachycardia and tachypnea. He is afebrile. Which of the following is most likely the cause?

A: Metal fume fever
B: Carbon monoxide toxicity
C: Phosgene toxicity
D: Acute myocardial infarction
E: Pulmonary embolism

The correct answer is C: Phosgene exposure occurs with the heating or combustion of chlorinated compounds, such as degreasers. Metal fume fever is related to welding, but the onset is 4-6 hours with fever, malaise, myalgias, and headache. Carbon monoxide toxicity would present earlier with headache, nausea, and vomiting. The patient is unlikely to have many risk factors for myocardial infarction or pulmonary embolism.

CME Question 2: A worker in a plant that manufactures isocyanates presents to the ED after having been exposed to phosgene in the past hour. The plant reports the exposure level was 100 ppm/min. What is the appropriate therapy if the patient is presently asymptomatic and has a normal chest x-ray?

A: Admit to the ICU and begin inhalational and systemic steroids for a 5-day course.
B: Begin steroid therapy and observe for 12-24 hours. If the patient remains asymptomatic and the chest x-ray is unchanged, discharge the patient with close follow-up. If a change in condition occurs, admit the patient to the ICU and continue therapy.
C: Release the patient back to work with instructions to return to the ED if symptoms develop.
D: Begin IV N-acetylcysteine therapy for a 5-day course.
E: None of the above therapies are appropriate.

The correct answer is B: The course of phosgene toxicity may include a latent period. If patients remain asymptomatic, they may be discharged only after observation for a minimum of 12 hours postadmission and close follow-up.

Pearl Question 1 (T/F): Solvents, paint removers, and dry cleaning fluids found in the common household may cause phosgene toxicity when exposed to a heat source.

The correct answer is True: Chemicals in these products may produce phosgene when exposed to heat.

Pearl Question 2 (T/F): Diuretics may be used in the routine management of phosgene toxicity.

The correct answer is False: This medication class should be avoided or, at least, given only after pulmonary artery catheter monitoring deems it appropriate. Patients may become hypotensive with significant toxicity, and, without monitoring, diuretics may worsen the patient`s condition.

Pearl Question 3 (T/F): Phosgene has the smell of bitter almonds.

The correct answer is False: Phosgene has the odor of newly mown hay or grass.

Pearl Question 4 (T/F): A patient with dyspnea who has been working with methylene chloride stripper and a heat gun may have phosgene and carbon monoxide toxicity.

The correct answer is True: Methylene chloride, when heated, may give off phosgene gas. Methylene chloride fumes are absorbed and converted to carbon monoxide endogenously, and levels may continue to rise after the exposure has stopped.

PICTURES

Section 11 of 12

Caption: Picture 1. British machine-gunners in anti-phosgene masks, Somme, 1915. (Photograph courtesy of the Imperial War Museum, London)
	View Full Size Image
	eMedicine Zoom View (Interactive!)
Picture Type: Photo
Caption: Picture 2. Phosgene structure.
	View Full Size Image
	eMedicine Zoom View (Interactive!)
Picture Type: Graph
Caption: Picture 3. The chest radiograph of a 42-year-old woman chemical worker 2 hours postexposure to phosgene. Dyspnea progressed rapidly over the second hour; PO2 was 40 mm Hg breathing room air. This radiograph shows bilateral perihilar, fluffy, and diffuse interstitial infiltrates. The patient died 6 hours postexposure. (Used with permission from Medical Aspects of Chemical and Biological Warfare, Textbook of Military Medicine, 1997, p 258)
	View Full Size Image
	eMedicine Zoom View (Interactive!)
Picture Type: X-RAY
Caption: Picture 4. A lung section of the patient whose chest radiograph is presented above. This patient died 6 hours following exposure to phosgene; the biopsy section was taken during postmortem examination. The section shows nonhemorrhagic pulmonary edema with few scattered inflammatory cells. Hematoxylin and eosin stain; original magnification X 100. (Used with permission from Medical Aspects of Chemical and Biological Warfare, Textbook of Military Medicine, 1997, p 258)
	View Full Size Image
	eMedicine Zoom View (Interactive!)
Picture Type: Photo
Caption: Picture 5. An anteroposterior (AP) portable chest radiograph of a male patient, who developed phosgene-induced adult respiratory distress syndrome. Notice the bilateral infiltrates and ground-glass appearance. (Image courtesy of Fred P. Harchelroad, MD, and Ferdinando L. Mirarchi, DO)
	View Full Size Image
	eMedicine Zoom View (Interactive!)
Picture Type: X-RAY
Caption: Picture 6. Chemical Terrorism Agents and Syndromes. Signs and symptoms. Chart courtesy of North Carolina Statewide Program for Infection Control and Epidemiology (SPICE), copyright University of North Carolina at Chapel Hill, www.unc.edu/depts/spice/chemical.html.
Picture Type: Image

BIBLIOGRAPHY

Section 12 of 12

• Balmes J: Phosgene. In: Olson KR, ed. Poisoning and Drug Overdose. 2nd ed. Appleton & Lange; 1994: 256.
• Bardana EJ: 8. Occupational asthma and allergies. J Allergy Clin Immunol 2003 Feb; 111(2 Suppl): S530-9[Medline].
• Borak J, Diller WF: Phosgene exposure: mechanisms of injury and treatment strategies. J Occup Environ Med 2001 Feb; 43(2): 110-9[Medline].
• British War Office: Medical Manual of Chemical Warfare. London; 1941: 31-38.
• Dombi A, Fekete ZA, Kiricsi I: In Situ Photocatalytic Reactor with FT-IR Analysis for Heterogeneous Catalytic Studies. Applied Catalysis 2000; 193: L5-L8.
• Ellenhorn MJ: Chemical warfare. In: Ellenhorn's Medical Toxicology. 2nd ed. Lippincott Williams & Wilkins; 1997: 1301-2.
• Kennedy TP, Michael JR, Hoidal JR, et al: Dibutyryl cAMP, aminophylline, and beta-adrenergic agonists protect against pulmonary edema caused by phosgene. J Appl Physiol 1989 Dec; 67(6): 2542-52[Medline].
• Nelson LS: Simple asphyxiants and pulmonary irritants. In: Goldfrank L, ed. Goldfrank's Toxicologic Emergencies. 6th ed. New York: McGraw-Hill; 1998: 1530.
• Ng TP, Tsin TW, O'Kelly FJ: An outbreak of illness after occupational exposure to ozone and acid chlorides. Br J Ind Med 1985 Oct; 42(10): 686-90[Medline].
• Noort D, Hulst AG, Fidder A, et al: In vitro adduct formation of phosgene with albumin and hemoglobin in human blood. Chem Res Toxicol 2000 Aug; 13(8): 719-26[Medline].
• Parrish JS, Bradshaw DA: Toxic inhalational injury: gas, vapor and vesicant exposure. Respir Care Clin N Am 2004 Mar; 10(1): 43-58[Medline].
• Phosgene Medical Experts Group: Phosgene: Information on Options for First Aid and Medical Treatment. 2006;[Full Text].
• Schelble DT: Phosgene and phosphine. In: Haddad LM, Shannon MW, Winchester J, eds. Clinical Management of Poisoning and Drug Overdose. 3rd ed. Philadelphia: WB Saunders; 1998: 960-3.
• Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH: Protective effects of N-acetylcysteine treatment after phosgene exposure in rabbits. Am J Respir Crit Care Med 1995 Mar; 151(3 Pt 1): 768-72[Medline].
• Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH: Postexposure treatment with aminophylline protects against phosgene- induced acute lung injury. Exp Lung Res 1997 Jul-Aug; 23(4): 317-32[Medline].
• Sciuto AM, Stotts RR: Posttreatment with eicosatetraynoic acid decreases lung edema in guinea pigs exposed to phosgene: the role of leukotrienes. Exp Lung Res 1998 May-Jun; 24(3): 273-92[Medline].
• Sciuto AM: Assessment of early acute lung injury in rodents exposed to phosgene. Arch Toxicol 1998 Apr; 72(5): 283-8[Medline].
• Sciuto AM, Strickland PT, Kennedy TP, et al: Intratracheal administration of DBcAMP attenuates edema formation in phosgene-induced acute lung injury. J Appl Physiol 1996 Jan; 80(1): 149-57[Medline].
• Sciuto AM, Stotts RR, Hurt HH: Efficacy of ibuprofen and pentoxifylline in the treatment of phosgene- induced acute lung injury. J Appl Toxicol 1996 Sep-Oct; 16(5): 381-4[Medline].
• Selden A, Sundell L: Chlorinated solvents, welding and pulmonary edema. Chest 1991 Jan; 99(1): 263[Medline].
• Sidell FR, Takafuji ET, Franz DR: Toxic inhalation injury. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Walter Reed Army Medical Center; 1997: 257-60.
• Sjogren B, Plato N, Alexandersson R, et al: Pulmonary reactions caused by welding-induced decomposed trichloroethylene. Chest 1991 Jan; 99(1): 237-8[Medline].
• Snyder RW, Mishel HS, Christensen GC 3d: Pulmonary toxicity following exposure to methylene chloride and its combustion product, phosgene. Chest 1992 Mar; 101(3): 860-1[Medline].
• Warden CR: Respiratory agents: irritant gases, riot control agents, incapacitants, and caustics. Crit Care Clin 2005 Oct; 21(4): 719-37, vi[Medline].
• Weiss SJ, Lesser SH: Hazards Associated with Metalworking by Artists. Southern Medical Journal 1997; 90: 665-671[Medline].

eMedicine Journals > Emergency Medicine > Toxicology > Toxicity, Phosgene

Please email us with any comments you have on our new chapter format.

Author Information | Introduction | Clinical | Differentials | Workup | Treatment | Medication | Follow-up | Miscellaneous | Test Questions | Pictures | Bibliography